Evidence map›Paper›PMID 31641391›Full record

ArticleCanadian respiratory journal2019

P27 Promotes TGF-

Yu-Heng Dai, Xiao-Qing Li, Da-Peng Dong, Hai-Bo Gu, Cheng-Ying Kong, Zhihao Xu

Open access · goldAbstract read
In one paragraph

Article in Canadian respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yu-Heng DaiHangzhou Women's Hospital, Hangzhou 310008, China.
Xiao-Qing LiSecond Hospital of Yingzhou District, Ningbo 315040, China.
Da-Peng DongThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Hai-Bo GuThe Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu 322000, China.
Cheng-Ying KongThe Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu 322000, China.
Zhihao XuThe Fourth Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu 322000, China.ORCID 0000-0003-2368-7661
Zhejiang University · CNHangzhou Women’s Hospital · CNNingbo No. 2 Hospital · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary fibrosis (PF), a progressive and life-threatening pulmonary disease, is the main pathological basis of interstitial lung disease (ILD) which includes the idiopathic pulmonary fibrosis (IPF). No effective therapeutic strategy for pulmonary fibrosis has been established. TGF-

Indexed as

AnimalsCell LineCell ProliferationCyclin-Dependent Kinase Inhibitor p27Gene Knockdown TechniquesHumansMaleMechanistic Target of Rapamycin Complex 2Mice, Inbred C57BLPulmonary FibrosisTransforming Growth Factor betaCyclin-Dependent Kinase Inhibitor p27Mechanistic Target of Rapamycin Complex 2Transforming Growth Factor beta

Identifiers

PMID31641391
PMCPMC6770332
OpenAlexW2973927826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.